Skip to main content
OpenTrials
Completed

NCT Number: NCT03059836

n3 PUFA and Muscle-disuse Atrophy in Young Women

This study will examine the influence of n3 PUFA supplementation on the rate of muscle atrophy in women undergoing 2 weeks of unilateral limb immobilization. Assessments in skeletal muscle strength and skeletal muscle volume will also me made before, after and in recovery from immobilization.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–30 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Exercise Metabolism Research Laboratory, McMaster Univeristy

Hamilton, Ontario, L8S 4K1, Canada

About this study

Biological aging is associated with the loss of skeletal muscle mass and strength resulting in compromised metabolic function and mobility. Throughout life, individuals will also experience periods of reduced physical activity/muscle disuse that independently lower muscle mass and strength accelerating the aging process. The losses in muscle mass with aging and disuse are underpinned by feeding-induced declines in rates of muscle protein synthesis. Thus, strategies to enhance muscle protein synthesis could have clinical implications for those who wish to maintain metabolic health and function during times of muscle disuse.

Supplementation with n3 PUFA-enriched fish oil has been shown to potentiate rates of muscle protein synthesis in response to simulated feeding in both younger and older adults. Fish oil supplementation also has been efficacious in enhancing skeletal muscle strength during a period of resistance exercise training. However, no study has examined the impact of fish oil supplementation to enhance muscle protein synthesis and offset declines in muscle mass/strength during a period of immobilization.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female
  • Aged 18-30 years

Exclusion criteria

  • Take any analgesic or anti-inflammatory drugs(s), prescription or non-prescription, chronically will be excluded
  • A history of neuromuscular problems or muscle and/or bone wasting diseases
  • Any acute or chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin- or non-insulin dependent diabetes or other metabolic disorders-all ascertained through medical history screening questionnaires
  • Use medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications)
  • Fish allergy

Treatment and study plan

n3 PUFA-enriched fish oil

Dietary Supplement

3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day

Placebo

Dietary Supplement

Organic Sunflower Oil 5000mg per day

Primary outcomes

  1. Muscle Volume

    Time frame: Baseline (0 days), After (14 days) of unilateral limb immobilization and at 14 days post immobilization

    Change in Muscle Volume Measured by Magnetic Resonance Imaging

Secondary outcomes

  1. Integrated Rates of Muscle Protein Synthesis

    Time frame: Before (0 days), During (0-14 days inclusive), and After (14-28 days inclusive) of unilateral limb immobilization

    Change in Muscle Protein Synthesis

  2. Skeletal Muscle Strength

    Time frame: Before (0 days), After (14 days) of unilateral limb immobilization and at 14 days Post immobilization

    Change in Skeletal Muscle Strength

  3. Muscle Lipid Composition

    Time frame: Baseline (-28 days), and at Before (0 days), After (14 days) of unilateral limb immobilization and at 14 days Post immobilization

    Change in Muscle Lipid Composition

Sponsors and collaborators

Lead sponsor

McMaster University

Other

Collaborators

  • University of Guelph

Registry information

Official study title

Effects of n3 PUFA Supplementation on the Attenuation of Muscle Disuse Atrophy in Young Women

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Feb 23, 2017
Registry last updated
Mar 22, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.